Abraham Chachoua, MD

  • Specialties: Solid Tumors, Oncology
  • Language: English
  • Phone: 212-731-5388

About Me

When I was a medical student in Melbourne, Australia, my father was diagnosed with multiple myeloma—a cancer that starts in bone marrow. During his treatment, I learned the tremendous value of communication between doctor and patient. I wanted to get the chance to deliver the best care possible to people like my father, which is what drew me to oncology. 

There were limited opportunities in the 1980s for oncologists in Australia—chemotherapy was not yet available there. So I came to NYU Langone, where chemotherapy and other modern advances in cancer treatment were available, for a research fellowship in medical oncology in 1985. When I landed in New York City, there was a tremendous sense of freedom that I’d never experienced anywhere else, and it’s still with me now. 

I specialize in the treatment of cancers of the lung and chest. I’m also conducting exciting research in immunotherapy, which helps us to enhance and harness the power of the immune system to eradicate cancer. This treatment causes fewer side effects and results in higher rates of remission.

But good patient care is just as much about art as it is science. If you color by numbers, you’ll create a nice painting, but if you instead pour your heart into it, you'll occasionally produce a masterpiece.

I embark on a journey with each patient, trying to make the road better and smoother. I spend time with patients—joking around, talking about family, and easing their pain.


Conditions and Treatments

testicular cancer, kidney cancer, bladder cancer, lung cancer

Credentials

Positions
  • Jay and Isabel Fine Professor of Oncology, Department of Medicine
  • Professor, Department of Urology
  • Assoc Dir Cancer Services Perlmutter Cancer Center
  • Co Director Thoracic Onc Research Prog
Education and Training
  • Fellowship, Alfred Hospital, Hematology/Oncology, 1984
  • Residency, Alfred Hospital, Rotating, 1982
  • MD from Monash University, 1978
Departments

Locations and Appointments

68 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Affinity
  • Affinity Exchange- Essential
  • Cigna EPO/POS
  • Cigna PPO
  • ElderPlan
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis Child Health
  • Fidelis Exchange
  • Fidelis Family Health
  • Fidelis Medicaid
  • Fidelis Medicare
  • GHI CBP
  • HIP Access I
  • HIP Access II
  • HIP Child Health
  • HIP EPO/PPO
  • HIP Family Health
  • HIP HMO
  • HIP Medicaid
  • HIP Medicare
  • HIP POS
  • HealthPlus Child Health (Amerigroup)
  • HealthPlus Family Health (Amerigroup)
  • HealthPlus Medicaid (Amerigroup)
  • HealthRepublic
  • HealthSmart (WTC)
  • Humana Medicare
  • Local 1199 PPO
  • MagnaCare PPO
  • Medicare
  • MetroPlus Child Health
  • MetroPlus Exchange Plans
  • MetroPlus Family Health
  • MetroPlus Medicaid
  • MultiPlan/PHCS PPO
  • NY Medicaid
  • NYS Empire Plan
  • Oscar
  • Oxford Exchange
  • Oxford Freedom
  • Oxford Liberty
  • Oxford Medicare
  • Tricare
  • UPN Elite
  • United Exchange- Compass
  • UnitedHealthcare Community & State Plan
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
  • Visiting Nurse Service (VNS) Medicare
  • WellCare Child Health
  • WellCare Family Health
  • WellCare Medicaid
  • WellCare Medicare
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.
NYU Medical Oncology Associates

160 East 34th Street
New York, NY 10016

Contact

Phone: 212-731-5388

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

“With our research, we aim to develop cancer treatments that cause fewer side effects.”

Abraham Chachoua, MD Oncologist

My Research

Dr. Abraham Chachoua specializes in the treatment of thoracic malignancies. Originally trained in Melbourne, Australia, he came to NYU to complete a research fellowship in medical oncology and was the recipient of an American Cancer Society career development award to evaluate the role of immune modulation in the treatment of solid tumors.

He has been involved in a number of clinical trials for the treatment of non small cell lung cancer.

Dr. Chachoua has a particular interest in the study of novel targeted therapies, how to use them earlier in the course of the illness and how to combine them with conventional chemotherapy for the treatment of advanced thoracic cancers. Among other interests he also attempts to use unique approaches for the integration of multimodality approaches for the treatment of locally advanced lung cancer.

Publications

  • Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial

    Golden, Encouse B; Chhabra, Arpit; Chachoua, Abraham; Adams, Sylvia; Donach, Martin; Fenton-Kerimian, Maria; Friedman, Kent; Ponzo, Fabio; Babb, James S; Goldberg, Judith; Demaria, Sandra; Formenti, Silvia C
    Lancet oncology. 2015 Jul. 16 (7): 795-803

  • Report of a Phase I Evaluation of Dose and Schedule of Interleukin-1 Alpha and Cyclophosphamide in Patients with Advanced Tumors: An Eastern Cooperative Oncology Group Study (PX990) and Review of IL-1-Based Studies of Hematopoietic Reconstitution

    Dutcher, Janice P; Neuberg, Donna; Atkins, Michael B; Tester, William J; Wadler, Scott; Stewart, James A; Chachoua, Abraham; Schuchter, Lynn M
    Journal of interferon & cytokine research. 2014 Jan. 376-384

  • Reflex Testing of Small Biopsy Specimens for EGFR and ALK Is Practical and Facilitates Implementation of the 2013 CAP/IASLC/AMP Guidelines for Lung Cancer Biomarker Testing in Patients with Advanced Stage Disease [Meeting Abstract]

    Krausert, A.; Sirdhar, D.; Pass, H.; Chachoua, A.; Suh, J.
    Modern pathology. 2014 FEB. 27 2 2: 483A-483A

Read All Publications (76)